Key result
Direct thrombin inhibitors, such as hirudin, are more effective than heparins for preventing deep vein thrombosis in high-risk orthopaedic patients.
Why the study?
What is the clinical efficacy of direct thrombin inhibitors compared to traditional heparins in patients requiring anticoagulation?
What is the clinical efficacy of direct thrombin inhibitors compared to traditional heparins in patients requiring anticoagulation?
Direct thrombin inhibitors such as hirudin and argatroban provide effective anticoagulation, particularly for DVT prevention in orthopaedic patients and management of heparin-induced thrombocytopenia.
Answers are grounded in this paper and cite their sources.
May support direct thrombin inhibitors over heparins for DVT prevention in high-risk orthopaedic patients; leaves open confirmation in randomized trials.
Direct thrombin inhibitors inactivate thrombin without the need for antithrombin and some inactivate not only thrombin but also fibrin-bound thrombin. Hirudin has been shown to be more effective than low-dose unfractionated heparin and low molecular weight heparin for the prevention of deep vein thrombosis in high-risk orthopaedic patients. Major studies are assessing the value of direct thrombin inhibitors in patients with acute coronary syndromes. Currently, argatroban is the drug of choice in patients with heparin-induced thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Andrew Nicolaides (2002) conducted a review in Deep vein thrombosis, acute coronary syndromes, heparin-induced thrombocytopenia. Direct thrombin inhibitors (Hirudin, argatroban) vs. Low-dose unfractionated heparin and low molecular weight heparin was evaluated. Direct thrombin inhibitors, such as hirudin, are more effective than heparins for preventing deep vein thrombosis in high-risk orthopaedic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: